ArticleProceedings of the National Academy of Sciences of the United States of America2017
Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Do-it-yourself protein arrays as high-throughput immunoassays enabled by confined droplets on patterned plasmonic chips.Nature communications · 2026Article
- Plasmonic biosensors and actuators for integrated point-of-care diagnostics.Npj biosensing · 2025Review
- Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.Immunologic research · 2024Review
- Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.International journal of nanomedicine · 2024Review
- Plasmonic Fluorescence Enhancement in Diagnostics for Clinical Tests at Point-of-Care: A Review of Recent Technologies.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Label-free MXene-assisted field effect transistor for the determination of IL-6 in patients with kidney transplantation infection.Mikrochimica acta · 2023Article
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip.Journal of nanobiotechnology · 2022Article
- Temporal reproducibility of IgG and IgM autoantibodies in serum from healthy women.Scientific reports · 2022Article
- Plasmonic nanosensors for point-of-care biomarker detection.Materials today. Bio · 2022Review
- A straightforward and sensitive "ON-OFF" fluorescence immunoassay based on silicon-assisted surface enhanced fluorescence.RSC advances · 2021Article
- Plasmonic Sensors for Extracellular Vesicle Analysis: From Scientific Development to Translational Research.ACS nano · 2020Review
- Ultrabright Fluorescence Readout of an Inkjet-Printed Immunoassay Using Plasmonic Nanogap Cavities.Nano letters · 2020Article
- A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation.Nature communications · 2019Article
- Plasmonic molecular assays: Recent advances and applications for mobile health.Nano research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of autoimmunity in cardiovascular (CV) diseases has been increasingly recognized. Autoimmunity is most commonly examined by the levels of circulating autoantibodies in clinical practices. Measurement of autoantibodies remains, however, challenging because of the deficiency of reproducible, sensitive, and standardized assays. The lack of multiplexed assays also limits the potential to identify a CV-specific autoantibody profile. To overcome these challenges, we developed a nanotechnology-based plasmonic gold chip for autoantibody profiling. This approach allowed simultaneous detection of 10 CV autoantibodies targeting the structural myocardial proteins, the neurohormonal regulatory proteins, the vascular proteins, and the proteins associated with apoptosis and coagulation. Autoantibodies were measured in four groups of participants across the continuum of hypertensive heart diseases. We observed higher levels of all 10 CV autoantibodies in hypertensive subjects (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.